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Pender-Related Differences
n the Clinical Presentation and
utcome of Hypertrophic Cardiomyopathy
acopo Olivotto, MD,* Martin S. Maron, MD,‡ A. Selcuk Adabag, MD,† Susan A. Casey, RN,†
aniela Vargiu, RN,* Mark S. Link, MD,‡ James E. Udelson, MD,‡ Franco Cecchi, MD,*
arry J. Maron, MD, FACC†
lorence, Italy; Minneapolis, Minnesota; and Boston, Massachusetts
OBJECTIVES The goal of this study was to assess gender-related differences in a multicenter population
with hypertrophic cardiomyopathy (HCM).
BACKGROUND Little is known regarding the impact of gender on the heterogeneous clinical profile and
clinical course of HCM.
METHODS We studied 969 consecutive HCM patients from Italy and the U.S. followed over 6.2  6.1
years.
RESULTS Male patients had a 3:2 predominance (59%), similar in Italy and the U.S. (p  0.24). At
initial evaluation, female patients were older and more symptomatic than male patients (47
23 years vs. 38  18 years; p  0.001; mean New York Heart Association [NYHA]
functional class 1.8  0.8 vs. 1.4  0.6; p  0.001), and more frequently showed left
ventricular outflow obstruction (37% vs. 23%; p 0.001). Moreover, female patients were less
often diagnosed fortuitously by routine medical examination (23% vs. 41% in male patients,
p  0.001). Female gender was independently associated with the risk of symptom
progression to NYHA functional classes III/IV or death from heart failure or stroke
compared with male gender (independent relative hazard 1.5; p 0.001), particularly patients
50 years of age and with resting outflow obstruction (p  0.005). Hypertrophic
cardiomyopathy-related mortality and risk of sudden death were similar in men and women.
CONCLUSIONS Women with HCM were under-represented, older, and more symptomatic than men, and
showed higher risk of progression to advanced heart failure or death, often associated with
outflow obstruction. These gender-specific differences suggest that social, endocrine, or
genetic factors may affect the diagnosis and clinical course of HCM. A heightened suspicion
for HCM in women may allow for timely implementation of treatment strategies, including
relief of obstruction and prevention of sudden death or stroke. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.043480–7) © 2005 by the American College of Cardiology Foundation
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eypertrophic cardiomyopathy (HCM) is a genetic cardiac
isease characterized by extreme heterogeneity in clinical
xpression and natural history (1–5). This diversity has
eriodically constituted an obstacle to a full understanding
f the clinical spectrum and the consequences of the disease
2). We and others (2–11) have previously investigated a
arge number of demographic and disease-related variables
hat potentially impact diagnosis, risk stratification, and
rognosis in HCM patients, but differences between the
enders with regard to clinical expression and outcome
emain largely unresolved.
Gender has proved important in the characterization and
anagement of a variety of acquired cardiovascular condi-
ions, including coronary artery disease and heart failure
12–17), aortic stenosis (18), atrial fibrillation (19), and
ustained ventricular arrhythmias (20). Because of the po-
From the *Regional Referral Center for Myocardial Diseases, Azienda Ospedaliera
niversitaria Careggi, Florence, Italy; †The Hypertrophic Cardiomyopathy Center,
inneapolis Heart Institute Foundation, Minneapolis, Minnesota; and ‡Hypertro-
hic Cardiomyopathy Center, Division of Cardiology, Tufts-New England Medical
enter, Boston, Massachusetts. Supported in part by grants from the Fondazione
nte Cassa di Risparmio di Firenze and the Italian Ministry for Scientific and
echnologic Research (PRIN 2004).u
Manuscript received December 7, 2004; revised manuscript received January 20,
005, accepted April 13, 2005.ential relevance of these considerations to genetic diseases
uch as HCM (21), in the present investigation we have
argeted the impact that gender may have on presentation
nd clinical course in a large cohort of HCM patients.
ETHODS
tudy population. A total of 969 consecutive patients with
CM were enrolled at three institutions: Azienda Ospe-
aliera Careggi, Florence, Italy; Minneapolis Heart Insti-
ute, Minneapolis, Minnesota; and Tufts-New England
edical Center, Boston, Massachusetts. Initial evaluation
i.e., study entry) was defined as the time of the first clinical
ssessment at each institution. Duration of follow-up to the
ost recent evaluation (or death) was 6.2  6.1 years.
chocardiography. Standard echocardiographic studies
ere performed with commercially available instruments.
agnitude and distribution of left ventricular (LV) hyper-
rophy was assessed, as previously described (22); LV
utflow obstruction was considered to be present when a
eak instantaneous subaortic gradient 30 mm Hg was
stimated with continuous wave Doppler echocardiography
nder basal (resting) conditions (10).
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August 2, 2005:480–7 Gender in HCMefinitions. HCM. Diagnosis was based on two-dimensional
chocardiographic evidence of a hypertrophied, non-dilated
V (maximum wall thickness 13 mm, or the equivalent
elative to body surface area in children), in the absence of
nother cardiac or systemic disease capable of producing the
agnitude of hypertrophy evident (1–4,22).
UDDEN CARDIAC DEATH. Sudden and unexpected collapse
ue to HCM occurring 1 h from the onset of symptoms
n patients previously experiencing a relatively stable or
neventful clinical course (23). Potentially lethal cardiovas-
ular events in which patients were either successfully
esuscitated from cardiac arrest or received appropriate
efibrillation shocks from an implanted cardioverter-
efibrillator (ICD) were regarded as equivalent to sudden
eath in the present analysis (23).
EART FAILURE-RELATED DEATH. Hypertrophic cardiomyopathy-
elated events occurring in the context of cardiac decompen-
ation and progressive disease course, including when compli-
ated by pulmonary edema or evolution to the end-stage phase
24), or fatal embolic stroke (9). Patients with advanced
efractory heart failure who received heart transplantation
ere considered equivalent to HCM-related heart failure
eaths (23).
tatistical methods. Data were expressed as mean  SD.
n unpaired Student t test was employed for comparison of
ormally distributed data. The chi-square test was utilized
o compare non-continuous variables expressed as propor-
ions. Relative risks and 95% confidence intervals were
alculated using univariate and multivariate Cox propor-
ional hazard regression models. Multivariate analyses were
erformed with a stepwise forward regression model, in
hich each variable with a p value of 0.05 (based on
nivariate analysis) was entered into the model. Survival
urves were constructed according to the Kaplan-Meier
ethod, and comparisons were performed using the log-
ank test. The p values are two-sided and considered
ignificant when 0.05. Calculations were performed with
PSS 8.0 software (SPSS Inc., Chicago, Illinois).
The clinical end points used in this study were death from
ny cause, all deaths related to HCM, sudden cardiac death
lone, as well as the combined end point including symp-
omatic progression to New York Heart Association
NYHA) functional classes III or IV or death from heart
ailure or embolic stroke (10). Deaths from all causes and all
eaths related to HCM were analyzed within the overall
tudy group of 969 patients, whereas sudden deaths alone
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
ICD  implanted cardioverter-defibrillator
LV  left ventricle/ventricular
NYHA  New York Heart Associationnd the combined end point were assessed only in the 867 aatients in NYHA functional classes I to II (after excluding
02 patients who were already in NYHA classes III to IV at
tudy entry).
ESULTS
revalence. Among the 969 HCM study patients, there
as a predominance of male patients (n  576; 59%)
ompared with female patients (n  393; 41%), which was
imilar in Italy and the U.S. (Table 1). This relationship did
ot change over the period of patient enrollment (Fig. 1).
ale predominance occurred from adolescence to mid-life,
ith reversed female predominance evident only among
atients 60 years old (Fig. 1).
aseline characteristics. CLINICAL FEATURES. At the time
f initial evaluation, female patients were 51  22 years, an
verage of 9 years older than male patients (42  18 years,
 0.001); a similar age difference of nine years was also
resent at the time of the first diagnosis of HCM (Table 1).
emale patients also had experienced more advanced heart
ailure symptoms of exertional dyspnea, as well as chest pain
r syncope (Table 1). Specifically, 57% of women (n 225)
ere symptomatic in NYHA functional classes II to IV at
nitial evaluation, compared with only 39% of men (n 
23; p  0.001).
ORPHOLOGY. Female patients showed slightly less maxi-
um LV wall thicknesses (21  5 mm vs. 22  6 mm in
ale patients, p  0.03), although the proportion of patients
ith extreme LV thickness (30 mm) was similar among
he genders (Table 1). Female patients also had smaller left
trial and LV end-diastolic dimensions (Table 1).
UTFLOW OBSTRUCTION AND MITRAL REGURGITATION. Fe-
ale HCM patients more frequently showed LV outflow
bstruction at rest, due to mitral valve systolic anterior
otion (gradient 30 mm Hg, average 72  31 mm Hg),
ompared with male patients (Table 1). At initial evalua-
ion, female patients with obstruction were older (age 51 
3 vs. 37  19 years, p  0.001) and more symptomatic
NYHA class 1.9 0.8 vs. 1.6 0.7, p 0.001) than male
atients. The proportion of female patients with obstruction
n NYHA functional classes III to IV was 24% (34 of 144),
ompared with only 11% of male patients (14 of 131; p 
.01). Moderate-to-severe mitral regurgitation was also
ore common in female patients, usually related to the
resence of outflow obstruction (16 [4%] vs. 11 [2%] for
ale patients, p  0.05).
riggers for echocardiographic diagnosis. Hypertrophic
ardiomyopathy was diagnosed fortuitously and unrelated to
ardiovascular symptoms or a family history of the disease in
ne-third of the study patients (Table 2). In these patients,
CM was initially suspected clinically by incidental recog-
ition of a heart murmur or abnormal electrocardiogram
uring routine examinations, with diagnosis subsequently
onfirmed by echocardiography. Such HCM diagnoses were
lmost 50% less likely among female patients (23% vs. 41%
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cardiomyopathy according to year of initial evaluation (top panel) and age
at initial evaluation (bottom panel).
HCM  hypertrophic cardiomyopathy; LV  left ventricular;
maximum; NYHA  New York Heart Association.
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Gender in HCM August 2, 2005:480–7n male patients; p  0.001). Conversely, female patients
ere most commonly identified by virtue of new or wors-
ning cardiac symptoms or acute cardiovascular events such
s onset of atrial fibrillation, embolic stroke, or resuscitated
ardiac arrest (Table 2). The genders were similar with
espect to HCM diagnosis initially triggered by a family
istory of the disease (Table 2).
utcome. Female gender was significantly associated with
he combined end point of long-term symptomatic progres-
ion to NYHA functional classes III or IV or death from
eart failure or stroke (Fig. 2, Table 3); this relationship was
lso evident when baseline clinical differences between the
enders with respect to age, NYHA functional class, trig-
ers for diagnosis, and presence of outflow obstruction were
aken into consideration by multivariate analysis (indepen-
ent relative hazard for female patients 1.5, p  0.001;
able 4). Of note, risk for adverse outcome was highest
mong female patients 50 years old at initial evaluation,
ompared with female patients 50 years or with male
atients (Fig. 3). In addition, female patients more often
xperienced nonfatal embolic stroke, despite a similar fre-
uency of atrial fibrillation between the genders (Table 3).
Conversely, no significant differences were identified
etween the genders with regard to all-cause mortality,
verall HCM-related deaths, and sudden cardiac death
Table 4, Fig. 2). In younger patients40 years, a trend was
dentified suggesting increased risk of sudden cardiac death
atients According to Gender
Male Patients Female Patients p Value
576 (59%) 393 (41%)
354 (58%) 251 (42%)
0.24*
222 (61%) 142 (39%)
38  18 47  23 0.001
42  18 51  22 0.001
1.4  0.6 1.8  0.8 0.001
353 (61%) 168 (43%)
191 (33%) 155 (39%)
32 (6%) 70 (18%)
150 (26%) 136 (35%) 0.005
57 (10%) 72 (18%) 0.001
26 (5%) 14 (4%) 0.21
131 (23%) 144 (37%) 0.001
58  37 62  38 0.3
22  6 21  5 0.03
55 (10%) 41 (10%)
155 (27%) 107 (27%)
192 (33%) 152 (39%) 0.17§
91 (16%) 54 (14%)
83 (14%) 39 (10%)
42  9 41  8 0.02
45  6 41  7 0.001
significant atherosclerotic narrowing of 1 coronary artery
flow obstruction 30 mm Hg; §overall comparison among
LVEDD  left ventricular end-diastolic diameter; Max igure 1. Distribution of 969 male and female patients with hypertrophicTable 1. Baseline Clinical Features of 969 HCM P
Parameters Overall
Number of (%) patients 969
U.S. 605
Italy 364
Age at diagnosis (yrs) 42  21
Age at initial evaluation (yrs) 46  20
NYHA functional class at initial
evaluation
1.6  0.7
I 521 (54%)
II 346 (36%)
III/IV 102 (10%)
Chest pain 286 (29%)
Syncope 126 (13%)
Coronary artery disease† 40 (4%)
Echocardiographic measurements
LV outflow gradient 30 mm Hg 275 (28%)
Mean outflow gradient (mm Hg)‡ 61  38
Max LV thickness (mm) 22  6
15 96 (10%)
16–19 262 (27%)
20–24 344 (35%)
25–29 145 (15%)
30 122 (13%)
Left atrium (mm) 42  9
LVEDD (mm) 43  7
*Overall comparison between the U.S. and Italy; †hemodynamically
documented by angiography; ‡among patients with resting LV out
classes of LV thickness.mong female patients (annual incidence 1.6% vs. 0.9% in
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August 2, 2005:480–7 Gender in HCMale patients), although this comparison did not achieve
tatistical significance (p  0.07). The proportion of pa-
ients who developed the end stage with systolic dysfunction
LV ejection fraction 50%) was also similar in the two
enders (22 to 393, 6% in female patients and 29 to 576,
%, in male patients; p  0.77). Finally, U.S. and Italian
atients did not differ with respect to the outcome end
oints by gender (p  0.1).
anagement. Treatment strategies did not different with
espect to gender (Table 3). Specifically, the proportion of
ale patients and female patients who underwent surgical
eptal myectomy or alcohol septal ablation, received an ICD
r dual-chamber pacemaker, or were treated pharmacolog-
cally with amiodarone or a beta-blocker did not differ
ignificantly between the two groups (Table 3). Female
atients were more often treated with disopyramide or
erapamil (p  0.01), probably related in part to their
igure 2. Relation of gender to overall hypertrophic cardiomyopathy (HCM
NYHA) functional classes III and IV, or heart failure (HF) or stroke d
Table 2. Circumstances Leading to Initial HC
Overall
(n  969)
Routine medical examinations 324 (33%)
Murmur 148 (15%)
Abnormal ECG 176 (18%)
Clinical manifestations 503 (52%)
Symptoms 365 (38%)
Dyspnea 135 (14%)
Chest pain 116 (12%)
Palpitations 76 (8%)
Dizziness (presyncope) 19 (2%)
Fatigue 19 (2%)
Acute cardiovascular events 138 (14%)
Atrial fibrillation 49 (5%)
Stroke 8 (0.8%)
Cardiac arrest (VF) 5 (0.5%)
Syncope 58 (6%)
Pulmonary edema 12 (1%)
Acute myocardial infarction 5 (0.5%)
Endocarditis 1 (0.2%)
Family history of HCM 142 (15%)
ECG  electrocardiogram; HCM  hypertrophic cardiomyncluding age, NYHA functional class, and left ventricular outflow obstruction
lready in NYHA functional classes III to IV at first evaluation were excludedigher prevalence of outflow obstruction and congestive
ymptoms.
ISCUSSION
nder-representation and delayed diagnosis. Hypertro-
hic cardiomyopathy is a diverse cardiac disease, usually
aused by mutant genes encoding proteins of the sarcomere,
nd transmitted as a Mendelian autosomal dominant trait
1,21). Therefore, the prevalence of HCM in the general
opulation is expected to be equal among the two genders
21). In contrast, however, the present multicenter study
ocuments a 3:2 predominance of male patients, consistent
ith most previous clinical reports showing a male majority
anging from 55% to 78% (2,3,7–10,24–30). Notably, the
revalence of male patients in our HCM population has not
hanged significantly over the last three decades, and was
ated mortality (left panel) and progression to New York Heart Association
right panel). Hazard plot based on multivariate Cox regression analysis
iagnosis According to Gender
ale Patients
(n  576)
Female Patients
(n  393) p Value
233 (41%) 91 (23%) 0.001
99 (17%) 49 (12%)
134 (24%) 42 (11%)
257 (44%) 246 (63%) 0.001
185 (32%) 180 (46%) 0.001
58 (10%) 77 (20%)
69 (12%) 47 (12%)
39 (7%) 37 (9%)
12 (2%) 7 (2%)
7 (1%) 12 (3%)
72 (12%) 66 (17%) 0.04
28 (5%) 21 (5%)
3 (0.4%) 5 (1%)
1 (0.2%) 4 (1%)
32 (6%) 26 (7%)
4 (0.7%) 8 (2%)
4 (0.7%) 1 (0.5%)
0 1 (0.5%)
86 (15%) 56 (14%) 0.42
y; VF  ventricular fibrillation.)-rel
eath (M D
M(gradient 30 mm Hg at rest) at initial evaluation. *Patients who were
from this analysis.
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Gender in HCM August 2, 2005:480–7onsistent in all age groups from childhood to middle age;
nly in those patients enrolled over 60 years of age was there
n excess of female patients.
In addition to the apparent under-representation of
omen with HCM in this cohort, our data also suggest a
elay in clinical identification. Indeed, women were older
y an average of about nine years and significantly more
ymptomatic than men, both at the time of their initial
CM diagnosis and when first evaluated at our institu-
ions. Among the subset of patients with LV outflow
bstruction, who are potential candidates for invasive
reatment options such as surgical septal myectomy or
Table 3. Features at Final Evaluation and Clin
Parameters Overall
Age at final evaluation or death (yrs) 51  20
Follow-up (yrs) 6.2  6.1
On medical treatment 648 (76%)
Beta-blockers 435 (45%)
Verapamil 318 (33%)
Disopyramide 37 (4%)
Amiodarone 142 (15%)
Major interventions for obstruction/
symptoms
Alcohol septal ablation 21 (2%)
Surgical septal myectomy 59 (6%)
Mitral valve replacement 10 (1%)
Heart transplantation 8 (0.8%
Pacemaker/ICD 81 (8%)
Final NYHA functional class 1.8  0.8
I 423 (44%)
II 303 (31%)
III/IV 243 (25%)
Atrial fibrillation 204 (21%)
Paroxysmal 131 (13%)
Chronic 73 (8%)
Nonfatal stroke 20 (2%)
HCM-related death 110 (11%)
Sudden death 59 (6%)
Heart failure/stroke-related 51 (5%)
Non–HCM-related death 58 (6%)
HCM  hypertrophic cardiomyopathy; ICD  implantable
able 4. Relation Between Clinical Variables at Initial Evaluation
azards Analysis)*
Variables
Death From Any Cause HCM-Rel
Relative Risk
(95% CI)
p
Value
Relative Ri
(95% CI)
emale gender — 0.13 —
iagnosis by routine
examinations‡
0.66 (0.45–0.97) 0.035 0.54 (0.34–0.
YHA functional
class II§
1.58 (1.08–2.30) 0.017 1.95 (1.20–3.
YHA functional
classes III/IV§
1.70 (1.04–2.80) 0.032 2.48 (1.34–4.
V outflow obstruction
(30 mm Hg at rest)
1.56 (1.10–2.22) 0.011 1.32 (1.02–2.
All models included age as a stratification factor (20, 20–39, 40–60,60 years); †p
f HCM-related symptoms or cardiovascular events; §as compared with NYHA claCI  confidence interval; HCM  hypertrophic cardiomyopathy; HF  heart failure
ssociation [NYHA] classes III to IV at study entry were excluded from these analyses); —lcohol septal ablation (1,4,5), the delay in HCM diag-
osis for women was even more striking (i.e., an average
f 14 years). Finally, although a substantial proportion of
ale patients were identified with HCM fortuitously (by
irtue of routine medical examinations unrelated to
ardiac symptoms), in female patients this diagnosis more
ften required clinically obvious disease manifestations
uch as onset of exertional dyspnea and chest pain, or
cute cardiovascular events including syncope, pulmonary
dema, and cardiac arrest.
There are a number of possible explanations for the
ifferences in prevalence of HCM by gender in our cohort.
utcome
Male Patients Female Patients p Value
48  19 56  22 0.001
6.6  6.5 5.5  5.6 0.01
365 (63%) 283 (72%) 0.01
251 (44%) 184 (47%) 0.17
170 (30%) 148 (38%) 0.01
14 (2%) 23 (6%) 0.01
78 (14%) 64 (16%) 0.23
9 (2%) 12 (3%) 0.12
28 (5%) 31 (8%) 0.06
5 (0.8%) 7 (2%) 0.24
6 (1%) 2 (0.5%) 0.86
41 (7%) 40 (10%) 0.16
1.7  0.8 2.1  0.9 0.001
299 (52%) 124 (32%)
172 (30%) 131 (33%)
104 (18%) 138 (35%)
115 (20%) 89 (23%) 0.6
74 (13%) 57 (15%)
41 (7%) 32 (8%)
6 (1%) 14 (4%) 0.007
58 (10%) 52 (14%) —
33 (6%) 26 (7%) —
25 (4%) 26 (7%) —
22 (4%) 36 (9%) —
verter-defibrillator; NYHA  New York Heart Association.
Outcome (Age-Adjusted Multivariate Cox Proportional
eath
Severe HF Symptoms†
or HF/Stroke Death Sudden Death
p
Value
Relative Risk
(95% CI)
p
Value
Relative Risk
(95% CI)
p
Value
0.51 1.50 (1.11–2.00) 0.001 — 0.97
0.010 0.75 (0.54–1.05) 0.09 0.57 (0.35–0.95) 0.031
0.006 2.08 (1.51–2.87) 0.001 1.94 (1.17–3.12) 0.094
0.004 n/a n/a
0.045 3.54 (2.64–4.75) 0.001 1.84 (1.14–2.98) 0.012
sion to NYHA functional classes III/IV; ‡as compared with diagnosis raised by onsetical O
)and
ated D
sk
87)
16)
60)
19)
rogres
ss I.; LV  left ventricular; n/a  not assessed (patients already in New York Heart
 variables removed from the final model.
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August 2, 2005:480–7 Gender in HCMhe apparent under-representation of women may reflect
ailed diagnoses due to reduced patient awareness regarding
ardiovascular risk (31–33), fewer indications for medical
creening programs (34–37), and clinician bias (31–33).
ack of attention to early clinical signs in women has been
reviously suggested in cardiac conditions such as coronary
rtery disease and heart failure, and may relate to denial and
reater focus on the health of others in the family (31–33).
oreover, the consistent reporting of male predominance in
CM cohorts (2,3,7–10,24–30), and the highly visible
udden deaths occurring largely in young male athletes with
CM (34), may well have promoted the misconception
hat this disease disproportionately and more severely affects
oung men (2). Of note, in this study the prevalence of
udden death among women with HCM was at least equal
o that in men, both in the overall study group and among
atients 40 years of age.
Besides these potentially important factors, delayed
CM diagnosis in women may be secondary to genetic and
ndocrine factors directly impacting phenotypic expression
21). For example, some investigators have even suggested
hat reduced penetrance and delayed disease onset may be
ore common in female patients with certain sarcomeric
ene mutations (21). In addition, as in coronary artery
isease, endocrine features associated with female gender
ay delay the development of the HCM phenotype or its
linical manifestations (38). Indeed, a protective effect of
strogens on development of secondary myocardial hyper-
rophy has been shown in animal models (39).
ender and clinical outcome. Over an average follow-up
f over six years, female patients with HCM had a 50%
reater risk than male patients of progression to severe,
isabling congestive symptoms or death from heart failure
r embolic stroke. This finding was independent of age and
unctional class at initial evaluation and, therefore, was not
olely attributable to delayed clinical diagnosis in women.
igure 3. Cumulative risk of progression to New York Heart Association
NYHA) functional classes III and IV, or heart failure (HF) or stroke death
elated to age at initial evaluation and gender. Patients who were already in
YHA functional classes III to IV at initial evaluation were excluded from
his analysis. Female patients 50 years versus female patients 50 years
f age (p 0.005); male patients50 years versus male patients50 years
f age (p  0.02).lternatively, the more progressive clinical course of HCM dn our female patients may be explained in part by the
reater prevalence of LV outflow obstruction compared
ith male patients, which in turn could be related to smaller
V cavity dimensions (25,40). Because outflow obstruction
as been shown to be a powerful independent predictor of
dverse outcome due to heart failure in HCM (10), the
ore frequent occurrence of obstruction in female patients
ikely contributed importantly to their more adverse long-
erm outcome. Other possibilities include an enhanced
usceptibility of female patients with HCM to the conse-
uences of atrial fibrillation (7), including heart failure,
mbolic stroke, and LV remodeling (25).
Finally, risk for heart failure-related clinical deterioration
nd death was greater among those female patients age 50
ears or older (average age, 65 years), as compared with
hose 50 years, or with male patients, suggesting that
ostmenopausal endocrine changes may impact clinical
ourse in HCM, as previously shown in coronary artery
isease (41). However, we observed no differences in man-
gement strategies between the genders after the diagnosis
f HCM with regard to pharmacologic or invasive treat-
ents (1), such as the ICD (42) or surgical and percutane-
us interventions aimed at relieving LV outflow obstruction
43). Thus, no potential biases in management strategies
ere identified for those patients already diagnosed with
CM.
The extent to which the two genders with HCM differ
ith regard to risk for disease progression cannot be totally
scribed to the known demographic and pathophysiologic
ariables, but suggests that other (as yet unresolved) mech-
nisms specifically related to the female gender may play an
mportant role. Specifically, women may be prone to disease
rogression for a variety of physiologic factors related to age,
ncluding more limited response to treatment and increased
omorbidity (44). Indeed, large epidemiologic studies of
on-HCM populations with secondary forms of LV hyper-
rophy (including the Framingham study) have consistently
eported an increased risk of death and cardiovascular
vents, or propensity for diastolic heart failure with pre-
erved systolic function in female patients (14–17).
otential treatment implications. That the diagnosis of
CM is less common and often delayed in female patients
s potentially of clinical relevance, and underscores the
mportance for heightened attention to this disease in
omen. In female patients with LV outflow obstruction and
eart failure symptoms, therapeutic options for pharmaco-
ogic, surgical, or percutaneous relief of the subaortic gra-
ient may be delayed, which is likely to have an impact on
he clinical course of the disease (1,4,6,43). Indeed, such a
oncern is consistent with the unfavorable long-term pro-
ression of disease demonstrated by our women with HCM,
argely related to outflow obstruction (10). Moreover,
omen were exposed to a risk for sudden death that was at
east equal to that of men, particularly when young. Thus,
elayed or failed HCM diagnoses may potentially deprive
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rotection offered by the ICD for primary prevention (42).
onclusions. This study documents a variety of distinc-
ions between the genders with regard to the clinical
resentation and course of HCM. Women with HCM were
nderdiagnosed and older, with more advanced disease than
en at initial evaluation. Furthermore, women showed
reater likelihood of marked symptom progression or death
ue to heart failure or stroke, often associated with LV
utflow obstruction. These gender-specific differences sug-
est that social, endocrine, or genetic factors may affect the
iagnosis and clinical course, and underscore the impor-
ance of heightened suspicion for HCM in women. Such
wareness may allow for timely implementation of treat-
ent strategies capable of improving clinical course, includ-
ng relief of obstruction and prevention of sudden death or
troke.
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